<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525564</url>
  </required_header>
  <id_info>
    <org_study_id>SMS106875</org_study_id>
    <nct_id>NCT00525564</nct_id>
  </id_info>
  <brief_title>Effects of Salmeterol on Walking Capacity in Patients With COPD</brief_title>
  <official_title>Effects of Salmeterol on Walking Capacity in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to test the following hypothesis:

      The acute changes in exercise tolerance during the endurance shuttle walk will be greater
      with salmeterol compared to placebo in patients with chronic obstructive pulmonary disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Little is known about the responsiveness of the endurance shuttle walking test
      (ESWT) to pharmacotherapy in patients with chronic obstructive pulmonary disease (COPD). This
      exercise testing modality needs to be further investigated because of its relevance for
      activity of daily living.

      Objective: To evaluate, in patients with COPD, the responsiveness of the ESWT to detect
      improvement in walking performance after single dose of salmeterol.

      Methods: In a randomised, double-blind, placebo-controlled, crossover study, 20 patients with
      COPD will perform, on two separate days, an ESWT at 80% of peak capacity, 2 hours after
      inhaling either a placebo or 50µg of salmeterol. Cardiorespiratory parameters will be
      monitored breath-by-breath during each walking test with a portable telemetric gas analyzer
      (Oxycom Mobile, Jaeger, Germany). Inspiratory capacities and Borg ratings for dyspnea were
      obtained every other minute throughout the tests.

      Planned analysis. The main outcome will be endurance time. This variable will be compared
      between the two treatment arms using a paired t test. The time course of the
      cardiorespiratory parameters and dyspnea over time will be compared between the two exercise
      modalities. Comparisons will be done using a repeated measure design (ANOVA). Significance
      level will be set at a p value of 0.05.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endurance time during an endurance shuttle walk</measure>
    <time_frame>acute response (2.5 hours) following the administration of the active and comparison drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspnea during endurance shuttle walk</measure>
    <time_frame>acute response following the administration of the study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardio-respiratory responses during an endurance shutlle walk</measure>
    <time_frame>acute response following the administration of the study medication</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo diskus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salmeterol diskus powder</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo diskus inhalation powder</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol diskus inhalation powder</intervention_name>
    <description>50 micrograms twice a day</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Serevent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 50 years

          -  smoking history &gt; 10 packs/year

          -  FEV1 &lt; 70% of predicted and FEV1/FVC &lt; 70%.

        Exclusion Criteria:

          -  respiratory exacerbation within the 2 months preceding the study

          -  history of asthma

          -  significant O2 desaturation (SaO2 &lt; 85%) at rest or during exercise

          -  presence of another pathology that could influence exercise tolerance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Maltais, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2007</study_first_submitted>
  <study_first_submitted_qc>September 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2007</study_first_posted>
  <last_update_submitted>September 5, 2007</last_update_submitted>
  <last_update_submitted_qc>September 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2007</last_update_posted>
  <keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <keyword>Exercise</keyword>
  <keyword>Endurance shuttle walking test</keyword>
  <keyword>Bronchodilation</keyword>
  <keyword>Salmeterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

